Introduction: Sweet syndrome (SS) is well known to be associated with underlying hematologic malignancies. The incidence and qualities of SS among novel targeted therapies for acute myeloid leukemia (AML) have not yet been described. Methods: Through retrospective review of 19,432 patients diagnosed with acute/chronic leukemia or myelodysplastic syndromes/myeloproliferative neoplasms (MDS+/−MPN) over 28 years, we calculated the incidence of SS in the setting of select hematologic malignancies and described the clinicopathologic characteristics of SS in patients with onset of SS after initiation of novel AML-targeted therapies. Results: Overall incidence of SS was 0.36% (95% CI: 0.27–0.45%), which was significantly higher among patients with AML (50/5,248, 0.94%; 95% CI: 0.71–1.25%). Nine AML patients were on 4 classes of novel targeted treatments – IDH1/2 inhibitor alone, FLT3 inhibitor, IDH2 and DOT1L inhibitor, and anti-CD33 therapy. In therapies inducing myeloid blast differentiation, SS occurred at later onset following treatment. Conclusions: In AML patients with fever and unusual skin lesions, physicians may consider SS earlier, which may shorten time to diagnosis. Future assessments of SS among patients treated with novel therapies for AML and molecular studies of biopsies may help further explain this dermatologic adverse event with earlier diagnosis and management of neutrophilic dermatoses in these patients.

1.
Rochet NM, Chavan RN, Cappel MA, Wada DA, Gibson LE. Sweet syndrome: clinical presentation, associations, and response to treatment in 77 patients. J Am Acad Dermatol. 2013;69(4):557–64.
2.
Nelson CA, Noe MH, McMahon CM, Gowda A, Wu B, Ashchyan HJ, et al. Sweet syndrome in patients with and without malignancy: a retrospective analysis of 83 patients from a tertiary academic referral center. J Am Acad Dermatol. 2018;78(2):303–9.e4.
3.
Dan H, Yanmei L, Yue X, Xian J. Sweet syndrome associated with malignancies: a retrospective analysis of 25 patients from West China hospital. Dermatol Ther. 2020;33(4):e13588.
4.
Maller B, Bigness A, Moiño D, Greene J. Sweet’s syndrome associated with hematological malignancies. Leuk Res. 2020;99:106461.
5.
Zheng S, Li S, Tang S, Pan Y, Ding Y, Qiao J, et al. Insights into the characteristics of sweet syndrome in patients with and without hematologic malignancy. Front Med. 2020;7:20.
6.
Joshi TP, Friske SK, Hsiou DA, Duvic M. New practical aspects of sweet syndrome. Am J Clin Dermatol. 2022;23(3):301–18.
7.
Orfaly VE, Shakshouk H, Heath M, Hamilton A, Ortega-Loayza AG. Sweet Syndrome: a review of published cases. Dermatology. 2023;239(4):664–9.
8.
Perl AE. The role of targeted therapy in the management of patients with AML. Blood Adv. 2017;1(24):2281–94.
9.
Fiorentini A, Capelli D, Saraceni F, Menotti D, Poloni A, Olivieri A. The time has come for targeted therapies for AML: lights and shadows. Oncol Ther. 2020;8(1):13–32.
10.
Su WP, Liu HN. Diagnostic criteria for Sweet’s syndrome. Cutis. 1986;37(3):167–74.
11.
von den Driesch P. Sweets syndrome (acute febrile neutrophilic dermatosis). J Am Acad Dermatol. 1994;31(4):535–56; quiz 57–60.
12.
Kazmi SM, Pemmaraju N, Patel KP, Cohen PR, Daver N, Tran KM, et al. Characteristics of Sweet Syndrome in patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015;15(6):358–63.
13.
Nelson CA, Stephen S, Ashchyan HJ, James WD, Micheletti RG, Rosenbach M. Neutrophilic dermatoses: pathogenesis, Sweet syndrome, neutrophilic eccrine hidradenitis, and Behçet disease. J Am Acad Dermatol. 2018;79(6):987–1006.
14.
Fathi AT, Le L, Hasserjian RP, Sadrzadeh H, Levis M, Chen YB. FLT3 inhibitor-induced neutrophilic dermatosis. Blood. 2013;122(2):239–42.
15.
Varadarajan N, Boni A, Elder DE, Bagg A, Micheletti R, Perl AE, et al. FLT3 inhibitor: associated neutrophilic dermatoses. JAMA Dermatol. 2016;152(4):480–2.
16.
Paudel A, Dhital R, Areoye G, Basnet S, Tachamo N. Sweet’s syndrome in a granulocytopenic patient with acute myeloid leukemia on FLT3 inhibitor. J Community Hosp Intern Med Perspect. 2020;10(3):275–8.
17.
Mohamed A. Enasidenib-induced Sweet syndrome with differentiation syndrome. Clin Case Rep. 2021;9(5):e04099.
18.
Dunn-Valadez S, Bathini S, Elston C, Rangaraju S, Stasi AD, Worth S, et al. IDH1 inhibitor-induced neutrophilic dermatosis in a patient with acute myeloid leukemia. Cancer Treat Res Commun. 2022;31:100560.
19.
Stubbins RJ, Karsan A. Differentiation therapy for myeloid malignancies: beyond cytotoxicity. Blood Cancer J. 2021;11(12):193.
20.
Merlant M, Lepelletier C, Battistella M, Vignon-Pennamen M-D, Duriez P, Moguelet P, et al. Acute myeloid leukemia and myelodysplastic syndrome: associated Sweet syndrome: a comparative multicenter retrospective study of 39 patients. J Am Acad Dermatol. 2021;84(3):838–40.
You do not currently have access to this content.